Pennsylvania-based pharmaceutical company Endo Health Solutions has agreed to pay $193 million to settle claims that it engaged in illegal off-label marketing of its pain relief medication, Lidoderm.
The company will pay $172 million to several states and the federal government to resolve whistleblower claims brought in the Eastern District of Pennsylvania and it will pay $21 million in criminal forfeiture and fines under a deferred prosecution agreement with the U.S. Attorney’s Office for the Northern District of New York, according to releases from the U.S. Department of Justice, the U.S. Attorney’s Office for the Eastern District of Pennsylvania and Endo Health Solutions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
